British Journal of Haematology, published by Wiley, is a leading journal in the field of hematology, with an impressive impact factor reflecting its significance in the medical research community. Established in 1955, the journal has consistently contributed to advancing knowledge in hematology, currently holding a prestigious Q1 ranking in the Scopus category of Hematology, placing it in the top 18% of the field. The journal encompasses a broad range of topics including clinical and laboratory aspects of blood disorders and hematological malignancies, making it an essential resource for hematologists, researchers, and healthcare professionals. With its commitment to publishing top-tier research and clinical studies, the British Journal of Haematology plays a critical role in shaping treatment approaches and improving patient outcomes worldwide. Please note that this journal does not offer Open Access options, ensuring that published content is rigorously curated for quality and relevance.

Nature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.

CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION is a premier academic journal published by Lippincott Williams & Wilkins, focusing on the latest advancements and research in the fields of nephrology and hypertension. Since its inception in 1992, this journal has been an essential resource for professionals seeking to stay at the forefront of kidney health and blood pressure management. With a distinguished ranking in the top quartile (Q1) for both Internal Medicine and Nephrology as of 2023, the journal is recognized for its high impact, currently holding a Scopus rank of #16 out of 81 in Nephrology, positioning it in the 80th percentile. Although not an open access journal, it provides crucial insights and expert opinions that cater to researchers, clinicians, and students committed to improving patient outcomes through evidence-based practice. The journal continues to emphasize its objectives of disseminating pivotal findings and fostering discussions that bridge the gap between clinical practice and research, making it an invaluable asset in the evolving landscape of nephrology and hypertension.

EUROPEAN JOURNAL OF HAEMATOLOGY, published by Wiley, serves as a vital resource for experts in the field of hematology, focusing on the latest advancements in blood disorders and therapies. With an ISSN of 0902-4441 and an E-ISSN of 1600-0609, this esteemed journal has been disseminating knowledge since 1986 and continues to thrive, converging its visionary approach through to 2024. Notably, it holds a distinguished Q2 ranking in Hematology and an impressive Q1 ranking in the broader category of Medicine (miscellaneous) as of 2023, highlighting its significant contribution to the scientific community. With a Scopus rank of #45/137 and a 67th percentile in the field, the journal is recognized for its rigorous peer-reviewed research, making it an indispensable publication for researchers, practitioners, and students aiming to stay at the forefront of hematological studies. Though not an open-access journal, it ensures broad accessibility to critical findings via its subscription model, thus fostering an informed and globally engaged audience.

Korean Journal of Internal Medicine, ISSN 1226-3303, E-ISSN 2005-6648, published by the Korean Association of Internal Medicine, stands as a vital resource in the field of internal medicine. Since its inception in 1961 and the shift to open access in 1986, this journal has consistently provided a platform for innovative research and clinical practices, contributing significantly to the advancement of medical knowledge in South Korea and beyond. With an impressive 2023 impact factor and a Q2 quartile ranking among internal medicine journals, it occupies a commendable position in Scopus rankings, holding the #54 slot out of 167 in the category. The journal emphasizes the dissemination of high-quality research findings, clinical reviews, and case reports, making it indispensable for researchers, professionals, and students eager to stay at the forefront of internal medicine. For authors and readers alike, the journal fosters an engaged and informed community, supporting the continuing education and professional development necessary in today's rapidly evolving medical landscape.

Hemato is a pioneering open-access journal dedicated to the field of hematology, published by the esteemed MDPI from its base in Basel, Switzerland. Launched in 2020, this journal aims to provide a platform for researchers, clinicians, and professionals to share significant findings and advancements in blood-related disciplines over a converged timeframe until 2024. With a commitment to disseminating high-quality research, Hemato seeks to foster collaboration and innovation in hematological studies, showcasing original articles, reviews, and clinical studies that contribute to expanding knowledge in this vital area. As an open-access journal, it promotes accessible scholarship, ensuring that groundbreaking research reaches a broad audience, thereby enhancing the impact on the global health community.

Bladder Cancer, published by IOS PRESS, is a premier open access journal dedicated to advancing the field of oncology and urology, with a specific focus on bladder cancer research and treatment. Established in 2015 and continuing through to 2024, this journal aims to disseminate high-quality, peer-reviewed research that contributes to the understanding, diagnosis, and management of bladder cancer, a critical area of concern in urological oncology. With a robust publication record now encompassing open access since 2023, Bladder Cancer ensures accessibility to vital research for clinicians, researchers, and scholars worldwide. The journal's rankings in Scopus reflect its commitment to excellence, holding a Q3 category in both oncology and urology, with Scopus ranks of #78 in Urology and #285 in Oncology, showcasing its growing influence in the scientific community. By fostering dialogue and innovation, Bladder Cancer serves as an essential resource for those committed to improving patient outcomes in bladder oncology.

Blood and Lymphatic Cancer-Targets and Therapy, published by DOVE MEDICAL PRESS LTD, is a vital open-access journal that has been disseminating crucial research and findings in the field of hematology and oncology since 2011. With its ISSN 1179-9889, this journal focuses on the latest therapeutic targets and innovative treatment strategies for blood and lymphatic cancers, contributing significantly to the advancement of knowledge and practice in this specialized area. Designed for researchers, healthcare professionals, and students alike, Blood and Lymphatic Cancer-Targets and Therapy aims to foster a deeper understanding of cancer biology and promote collaborative efforts leading to novel therapeutic interventions. The open-access model ensures that research findings are readily accessible to a global audience, underscoring the journal's commitment to enhancing patient care and fostering educational growth in the cancer domain.

Therapeutic Advances in Musculoskeletal Disease is a premier, peer-reviewed journal published by SAGE Publications Ltd, focusing on the latest advancements in the understanding and treatment of musculoskeletal disorders. Since becoming an Open Access journal in 2019, it has significantly broadened its reach, providing researchers, clinicians, and practitioners with unfettered access to high-quality studies and reviews from 2009 to 2024. With an impressive impact factor reflected by its Q1 rank in Orthopedics and Sports Medicine and Q2 rank in Rheumatology for 2023, the journal occupies a critical position within its field. Ranked #31 out of 321 in Orthopedics and Sports Medicine and #17 out of 73 in Rheumatology on Scopus, it emphasizes both the clinical and scientific aspects of musculoskeletal health. This journal serves as a vital resource for advancing knowledge, encouraging collaboration, and fostering innovative treatment methods within the musculoskeletal community.

BLOOD, published by the American Society of Hematology, is a premier peer-reviewed journal in the fields of Biochemistry, Cell Biology, Hematology, and Immunology. With an impressive impact factor and ranking in the top quartiles (Q1) across multiple disciplines, BLOOD is essential reading for researchers and professionals seeking to stay updated on the latest advancements in hematology and related fields. The journal has been a cornerstone of hematological research since its inception in 1946, providing a platform for rigorous scientific inquiry and discourse. Its commitment to publishing high-quality original research, comprehensive reviews, and insightful editorials makes it a vital resource for students, practitioners, and scientists alike. By offering exceptional access to influential publications, BLOOD continues to shape the future of hematology and enhance understanding of blood-related disorders, marking its vital role in advancing both basic and clinical research.